

INSULIN THERAPY IN TYPE 2 DIABETES MELLITUS

Dr Tan Seng Kiong, Dr Tan Hwee Huan, A/Prof Sum Chee Fang

ABSTRACT

Initiation of insulin therapy is challenging in the primary care setting without nursing support. Doctors have to prepare their practices to deal with these challenges in order not to delay insulin therapy when needed.

Keywords: insulin therapy, challenges, strategies

SFP2025; 51(2): 17-21

INTRODUCTION

Insulin therapy is initiated for patients early in their course of diabetes to relieve symptoms of severe hyperglycaemia or in the hope of achieving remission and during the course of diabetes to attain optimal control.^{1,2} In the specialist outpatient setting, successful initiation of insulin therapy is very much dependent on having dedicated diabetes nurse educators (DNE) who would ensure the smooth transition of the therapy for the patient and the doctor. With the increasing prevalence of diabetes in Singapore, most patients with Type 2 Diabetes Mellitus (T2D) are now receiving their care in the community. The initiation of insulin in the polyclinics is facilitated by nurses trained in diabetes management who can assist with the initiation, optimisation and intensification of the therapy. For family practices that are not often supported by DNE, initiation of insulin therapy may be challenging. This article hopes to share some clinical pointers to help these doctors prepare their practices for their patients who require insulin therapy.

EMPOWERING PATIENTS DURING INSULIN INITIATION

A good resource that can be obtained easily online is the Royal College of Nursing booklet on “Starting injectable treatment in adults with Type 2 diabetes”.³ The chapter on a step-by-step guide to insulin therapy includes details on first appointment/first injection, choosing a delivery device,

teaching injection technique, choosing injection site, rotating injection sites, timing of injection, insulin dosage, storage, and checklist. The following chapter on essential education elaborates on the subjects to be covered at three stages of insulin therapy: immediately upon starting the therapy; within the first few weeks of starting therapy; and once the patient is feeling more confident with the therapy. This is a very easy book to read and provides a simple, comprehensive, and practical overview for the initiation of insulin therapy.

In preparation for the conversation on insulin therapy with the patient, it is recommended that the practice gathers together the armamentarium or tool kit required for the education and support of insulin therapy. This could include:

1. Blood glucose monitoring (BGM) gadgets – glucometer, strips, lancets (include safety lancets that do not require a separate lancing device), lancing device, record book, swabs, and sharps disposal. If available, Flash (intermittent) continuous glucose monitoring demonstration kit or online video.^{4,5}
2. Insulin therapy gadgets: vial, disposable prefilled pens, self-fill pens, syringes (30, 50, 100cc; 6 and 8mm), pen needles (gauge 31-33, length 4, 5 and 6mm), insulin wallets, sharps disposal, and swabs.^{3,6}
3. Written information on instructions for insulin dose and time, delivery device, rotating sites, hypoglycaemia management, and sick day management.
4. Travel advice and letter for airport securities.

The doctor should be prepared to spend time to proactively engage and work with the patient to deal with the challenges faced with insulin therapy.^{7,8} These anticipated barriers and challenges could be explored with the patient early on and during the course of diabetes to ensure timely initiation of insulin therapy when required. The doctor should be careful not to use insulin therapy as a threat for poor control but rather as an effective therapeutic option. The mnemonic PICK DMP is a useful reminder of the common barriers and challenges encountered. **Table 1** below elaborates on the use of this mnemonic.

DR TAN HWEE HUAN
Senior Consultant
Khoo Teck Puat Hospital

A/PROF SUM CHEE FANG
Senior Consultant
Khoo Teck Puat Hospital

Table 1: Common barriers in insulin initiation and proposed strategies

Challenges/Barriers		Assess	Strategies
Pain	It is going to be painful.	If the fear is perceived or real; show range of needles currently available (smallest: 31-33 G x 4-5 mm) as compared to those used for drawing of blood (16-21 G x 12-40 mm).	Demonstrate how insulin is administered. Share experiences of others/self. Offer trial injection. Offer insulin port or pump for those on multiple dose injections.
Inconvenience Cost	It will disrupt my lifestyle. It is going to be expensive.	Current and desired lifestyle – daily activities at home, work (shift work) or school; meal times – regularity; driving; leisure, physical activity, travel, fasting needs; storage – fridge at home; insulin wallets. Cost of current oral therapy, financial status, eligibility for funding. Understanding of cost of complications.	Demonstrate the convenience of insulin pens. Offer to initiate regimen that will lead to least disruption. Offer cost-saving measure or funding application.
K(C)ompetence	I'm not sure I can handle so much.	Learning abilities (cognitive function), self-care skills (self-monitoring of blood glucose and interpretation of results), literacy, diabetes numeracy, dexterity, vision, support	Offer support for first jab and ongoing support until confident. Offer support from diabetes centre/specialist clinic if more assistance/training required. Goal setting to be decided with patient using SMART (specific, measurable, achievable, relevant/realistic, and time-based) and review and adjusted accordingly.
Denial	I'll try harder; I don't need this yet. I feel fine.	Understanding of diabetes as a "silent killer", concept of HbA1c as predictor of complication, progression of diabetes and failure of oral agents (not patient's failure).	Offer individual or group education, peer support. Stage approach to initiation of insulin – raise awareness and understanding of glycaemic levels and desired targets through SMBG training and interpretation. Offer trial of insulin with review date.
Myth	If I go on insulin, I'll lose a foot, my kidney or end up dying. If I start, I will need to continue for life.	Source of information; level of fears and misunderstanding. Understanding of hyperglycaemia as cause of complications and need to achieve glycaemic targets. Understanding of sick-day management and risk of hypoglycaemia. Understanding of need for insulin in Type 2 Diabetes – insulin deficiency and insulin resistance. Understanding of benefits of early initiation of insulin.	Offer evidence from trials with regards to safety and efficacy of insulin therapy; other patient's testimonies; peer support group. Reinforce sick day management and hypoglycaemia management.
Phobia	I can't possibly give myself an injection. I'll have low sugar reactions. I'll get fat.	If there's needle phobia. Understanding of action of insulin, why hypoglycaemia happens, how to avoid and manage if it happens. Ability to manage hypoglycaemia. Indication for insulin, fear of weight gain and understanding of reason for weight gain and measures to avoid excessive weight gain.	Offer to refer to a psychologist. Caregiver to perform jabs. Offer auto-injector, insulin port. Offer measures to reduce risk of hypoglycaemia – start with low dose and close monitoring of response and review during optimisation of therapy. Offer measures to reduce weight gain – lifestyle advice, concomitant use with SGLT-2 inhibitors, GLP-1RA, and metformin.

SELECTION OF INSULIN THERAPY AND REGIME

The prescription of insulin and therapy regime needs to be tailored to the patient. Insulin regimens such as basal only, basal-plus, basal-bolus, or pre-mixed insulin are reasonable options if the patient can adhere to it. The ideal dosing of insulin is to mimic normal pancreatic insulin physiology; therefore it is important to be familiar with the pharmacokinetic profiles of the insulin prescribed.


STEPS TO INSULIN INITIATION AND INTENSIFICATION OF THERAPY

The doctor should consider initiating insulin therapy when:

1. Glycaemic targets are not met on optimal treatment with oral glucose-lowering agents.
2. The patient has symptomatic hyperglycaemia.

There are various formulations of insulins that the doctor may choose. The Appropriate Care Guide (ACE) on Initiating Basal Insulin in Type 2 Diabetes Mellitus¹⁰ is a useful resource to guide doctors in their choice of basal insulin and steps in titration. Basal insulin can be started at a dose of 0.1-0.2 units/kg/day depending on the patient’s age, comorbidities, and blood glucose profile. The dose can be titrated by 2-4 units once or twice a week, until the target fasting blood glucose is achieved. Should the patient’s HbA1c remain poorly controlled, and the patient has postprandial hyperglycaemia or a basal insulin dose that exceeds 0.5 units/kg/day, the doctor should consider adding on prandial insulin. This can be done in form of basal-plus, basal-bolus, or premixed (biphasic) insulin, depending on the patient profile. Injectable GLP-1 receptor agonists may also be considered.

Figure 1: Algorithm for insulin therapy




Insulin prescription is made easier if the doctor can figure out the glycaemic profile of the patient.^{1,9} A prescription of BGM to be performed by the doctor, patient, or caregiver should first be given to evaluate the glycaemic profile of the patient. It can be done using the FITT model as illustrated in **Table 2** below:

Table 2: FITT model for Capillary Blood Glucose Monitoring


Frequency	Intensity	Time	Targets – to be individualised
Daily for 3 days	2 points	BT & FBG	FBG: 4-7mmol/L; BT: 7-10 mmol/L
Once a week	2 points	FBG & PD	FBG: 5-8mmol/L; PD: 5-8mmol/L
On off days or weekend	2 points, up to 7	Before and 2 hours after meals & BT	Pre-meal BG <7 mmol/L; post-meal BG <10 mmol/L

Legend: FBG: fasting blood glucose; PD: pre-dinner; BT: bedtime

Figure 2 : Common patterns of glucose profiles and possible therapeutic interventions.



Desired blood glucose levels after initiation of insulin therapy:



BLOOD GLUCOSE MONITORING

In patients receiving insulin therapy, blood glucose monitoring is important to help our patients identify patterns in their blood glucose fluctuations. This can be done in the form of a capillary blood glucose or a flash continuous glucose monitoring system. The frequency of monitoring needs to be individualised in order to improve patient compliance and obtain sufficient information to have meaningful interpretation of the data. The target blood glucose levels also need to be individualised according to the patient’s comorbidities and risk of hypoglycaemia. **Table 2** provides some of the common used monitoring frequency and blood glucose targets, and **Figure 2** summarises the commonly encountered blood glucose profiles and their interventions.

BEWARE OF HYPOGLYCAEMIC UNAWARENESS

Hypoglycaemic unawareness occurs when the patient does not develop the early warning symptoms of hypoglycaemia when their blood glucose levels are low. These symptoms include tremors, palpitations, and diaphoresis. This may occur when the patients have repeated episodes of hypoglycaemia or concomitant autonomic neuropathy, and this results in a significant increase risk of developing severe hypoglycaemia. Patients with hypoglycaemic unawareness should be advised to increase their glycaemic targets for a few weeks to avoid hypoglycaemia.

CONCLUSION

In summary, insulin therapy is an important and effective therapeutic option in the management of Type 2 diabetes. Initiation, optimisation, and intensification will be challenging if doctors are not prepared to deal with the challenges. With careful preparation as proposed above, insulin therapy can be initiated safely and effectively even in primary care settings.

REFERENCES

1. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009. PMID: 38078590; PMCID: PMC10725810.
2. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. *The Lancet Diabetes & Endocrinology*. 2013 Sep 1;1(1):28-34.
3. Royal College of Nursing. Starting injectable treatment in adults with Type 2 diabetes. RCN guidance or nurses [pdf]. 2012 [accessed 1 Dec. 2020] Available from: https://www.pennine-gp-training.co.uk/res/Starting_percent20Insulin_percent20in_percent20Type_percent20_2_percent20DM.pdf
4. Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, McGill JB, Polonsky W, Price D, Aronoff S, Aronson R. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. *Annals of Internal Medicine*. 2017 Sep 19;167(6):365-74.
5. Carlson AL, Mullen DM, Bergenstal RM. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. *Diabetes Technology & Therapeutics*. 2017 May 1;19(S2):S-4.
6. Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, Smith MJ, Wellhoener R, Bode BW, Hirsch IB, Kalra S. New insulin delivery recommendations. In *Mayo Clinic Proceedings* 2016 Sep 1 (Vol. 91, No. 9, pp. 1231-1255). Elsevier.
7. Karter AJ, Subramanian U, Saha C, Crosson JC, Parker MM, Swain BE, Moffet HH, Marrero DG. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. *Diabetes Care*. 2010 Apr;33(4):733-5.
8. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. *Patient Preference and Adherence*. 2016; 10:1299.
9. Kalra S, Czupryniak L, Kilov G, Lamptey R, Kumar A, Unnikrishnan AG, Boudiba A, Abid M, Akanov ZA, Latheef A, Araz M. Expert Opinion: Patient Selection for Premixed Insulin Formulations in *Diabetes Care*. *Diabetes Therapy*. 2018 Dec 1:1-5.
10. Appropriate Care Guide (ACE): Initiating basal insulin in type 2 diabetes mellitus. 2022. [accessed 1 Jan 2024] Available from: [https://www.ace-hta.gov.sg/docs/default-source/acgs/initiating-basal-insulin-in-t2dm-\(updated-on-10-june-2022\)e789e615718e4371b3353ea5afaa599f.pdf](https://www.ace-hta.gov.sg/docs/default-source/acgs/initiating-basal-insulin-in-t2dm-(updated-on-10-june-2022)e789e615718e4371b3353ea5afaa599f.pdf)

RECOMMENDED READINGS:

1. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009. PMID: 38078590; PMCID: PMC10725810.
2. Royal College of Nursing. Starting injectable treatment in adults with Type 2 diabetes. RCN guidance or nurses [pdf]. 2012 [accessed 1 Dec. 2020] Available from: https://www.pennine-gp-training.co.uk/res/Starting_percent20Insulin_percent20in_percent20Type_percent20_2_percent20DM.pdf
- 3.
4. Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, Smith MJ, Wellhoener R, Bode BW, Hirsch IB, Kalra S. New insulin delivery recommendations. In *Mayo Clinic Proceedings* 2016 Sep 1 (Vol. 91, No. 9, pp. 1231-1255). Elsevier.
5. Appropriate Care Guide (ACE): Initiating basal insulin in type 2 diabetes mellitus. 2022. [accessed 1 Jan 2024] Available from: [https://www.ace-hta.gov.sg/docs/default-source/acgs/initiating-basal-insulin-in-t2dm-\(updated-on-10-june-2022\)e789e615718e4371b3353ea5afaa599f.pdf](https://www.ace-hta.gov.sg/docs/default-source/acgs/initiating-basal-insulin-in-t2dm-(updated-on-10-june-2022)e789e615718e4371b3353ea5afaa599f.pdf)

LEARNING POINTS

- **Insulin therapy should be introduced as an effective therapeutic option and not used as a threat for poor control.**
- **Challenges faced with insulin therapy should be managed with patients early in their course of diabetes.**
- **Clinicians have to be prepared to deal with the challenges faced with insulin therapy.**

OBEISITY UPDATES: UNDERSTANDING OBEISITY AS A DISEASE AND INTERMITTENT FASTING

Dr Benjamin Lam

ABSTRACT

Obesity is now recognised as a chronic disease that needs chronic treatment to treat or prevent obesity-related complications. This article discusses the biology of weight regulation as a basis to understanding obesity as a disease, and to appreciate the complex and multifactorial nature of the obesity problem. Finally, the article highlights the dietary approaches as part of the multi-pronged approach to treating obesity and gives a brief update on intermittent fasting.

Keywords: Obesity, Chronic Disease, Body Weight Regulation, Intermittent Fasting

SFP2025; 51(2): 22-26

INTRODUCTION


Over the last 40 years, the prevalence of obesity has risen substantially in almost all regions of the world, such that there are now more than 600 million people with obesity worldwide.^{1,2} This increasing burden of obesity affects all regions, including Singapore.¹ The National Health Survey (NHS 1992-2010) reports that 10.8 percent of adult Singaporeans were obese in 2010, more than double the prevalence in 1992.³ Results from recent national health surveys, the National Population Health Survey (NPHS 2017-2022), suggest a continuing of this trend after a brief period of stabilisation from 2010 to 2017.⁴

BIOLOGY OF WEIGHT REGULATION

The body's adipose tissue represents energy stores to survive energy-scarce conditions. Hence, it would not be surprising that that body weight (or more accurately, adipose tissue in the body) is tightly regulated by an extremely complex neuroendocrine energy balance circuitry, which is composed of specific nuclei in various brain regions, most prominently the hypothalamic arcuate nucleus (ARC), the paraventricular nucleus, the lateral hypothalamic area, and the nucleus of solitary tract of the hindbrain^{5,6} (refer

to **Figure 1**). Under relatively constant environmental conditions, this regulatory system senses and processes various metabolic signals regarding the current energetic status and adjusts the metabolic responses to maintain a stable weight without conscious control.⁵ This homeostatic regulation of body weight is similar to the regulation of other physiologic parameters, such as body temperature, blood pressure, or blood glucose, where a "set point" seems to exist and deviation from this "set point" elicits a compensatory response in an opposite direction to restore this body weight "set point". Therefore, weight regain after weight loss is physiological^{7,8}{Sumithran, 2013, The defence of body weight: a physiological basis for weight regain after weight loss} and not necessarily due to a failure of conscious efforts (to lose weight).

Figure 1: Model for regulation of the hindbrain response to satiety signals by hormonal input from the ARC⁶



Additionally, there exists a different set of neuroendocrine signals that guides food intake based upon the reward value of the food, also known as the reward or "hedonic" system.^{5,9} The brain regions responsible for this reward system are dispersed in the corticolimbic structures, and a primary characteristic of this system is its ability to override the signals from the homeostatic circuits as described.⁵ Hence, the reward system is non-homeostatic with regard to energy balance. This system integrates basic midbrain and hindbrain functions with more complex cortical functions involving arousal at the sight of palatable food items and the procurement of food, mediating the "liking" (level of pleasure or reward) and "wanting" (the motivation or drive to consume food), which are subconscious processes.⁵ In human studies, functional MRI (fMRI) studies have shown overactivation of reward-encoding brain regions and/or deficiency in cortical inhibitory networks in people with obesity.⁵

DR BENJAMIN LAM
Senior Consultant Family Physician
Department of Family and Community Medicine
Khoo Teck Puat Hospital

Clinical Director
Integrated Care for Obesity and Diabetes (ICOD)
Khoo Teck Puat Hospital

OBESITY AS A DISEASE: PATHOPHYSIOLOGY AND HEALTH CONSEQUENCES

With the understanding of the biology of weight regulation, obesity (defined as a disproportionate body weight for height with an excessive accumulation of adipose tissue¹⁰) is now understood to signify an abnormal physiological state whereby there has been a surplus intake of energy and an elevated body weight set point is now defended.^{5,11} The factors known to cause this are complex and multiple, and they range from genetic to environmental to emotional factors, which are well-known to be potent modulators of appetite.⁹ Twin, family, and adoption studies show that the rate of heritability of BMI is high, ranging from 40 to 70 percent,¹² demonstrating a major genetic component.

In addition to syndromic and monogenic forms of obesity, genome-wide association studies (GWAS) have identified more than 700 independent loci associated with BMI and/or obesity.¹³⁻¹⁵ Environmental and lifestyle factors favouring a positive energy balance and weight gain include increasing per capita food supplies and consumption, particularly of highly processed, energy-dense, and palatable foods that are often served in large portions; decreased amounts of time spent in occupational physical activities and displacement of leisure-time physical activities with sedentary activities such as television-watching and use of electronic devices; the growing use of medicines that have weight gain as a side effect; stress; and inadequate sleep.¹²

More recent studies have identified a potential role for the microbial content of the gut in determining a broad range of metabolic abnormalities, including obesity.^{16,17} The evidence supporting causation includes animal studies that show that obesity, as a phenotype, is transmittable via the transfer of gut microbiota from the obese (mice/humans) to germ-free mice,^{18,19} and mechanistic studies that demonstrate the possible mechanisms linking the gut microbiota with obesity.^{16,20}

Obesity is not benign. The failure of adipose tissues to continually expand leads to pathological changes in the adipose tissue, which is characterised by macrophage invasion and/or increased release of pro-inflammatory adipokines and decreased release of anti-inflammatory adipokines such as adiponectin¹⁰ (refer to **Figure 2**). In addition, this failure to further expand and act as a “metabolic sink” results in harmful ectopic fat deposition in lean tissues such as the heart, liver, pancreas, and kidneys.¹⁰ These two phenomena contribute to a pro-inflammatory and insulin-resistant milieu, giving rise to metabolic complications such as type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease (CVD).^{10,21} Additionally, the physical forces as a result of excessive adipose tissue can give rise to biomechanical consequences (such as Obstructive Sleep Apnea (OSA) and low back pain), and obesity as a condition has been associated with various psychosocial issues, impacting on mental health.²²

All these adverse consequences affect quality of life, increase healthcare costs, and finally, increase mortality.²³ Therefore, based on the current knowledge that the development of obesity results from established pathophysiology, with attending health consequences (complications, morbidities, and mortality), obesity fulfils the criteria for a disease state and is now determined to be a disease,¹¹ rather than just a lifestyle risk factor. Several associations and organisations, including the World Health Organisation (WHO), have now declared obesity as a disease (refer to **Figure 3**), and this is an important first step in tackling the problem of obesity, which has emerged as an epidemic that poses an unprecedented public health challenge.¹¹

Figure 2: Pathological changes in adipose tissue¹⁰




Figure 3: Associations or organisations that have declared obesity is a disease¹¹

Box 1 Associations or organizations that have declared obesity is a disease
• National Institutes of Health
• US Food and Drug Administration
• Federal Trade Commission
• American Medical Association
• World Health Organization
• American College of Physicians
• American Association of Clinical Endocrinologists
• American College of Cardiology
• The Endocrine Society
• American Academy of Family Physicians
• Institute of Medicine
• The Obesity Society
• World Obesity Federation
• American Heart Association
• American Diabetes Association
• American Academy of Family Physicians
• American Society for Reproductive Medicine
• American Urologic Association
• American College of Surgeons

Data from Kahan S, Zvenyach T. Obesity as a disease: current policies and implications for the future. *Curr Obes Rep* 2016;5(2):291-7; and Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obes Rev* 2017;18(7):715-23.

SEVERITY OF OBESITY AND TREATMENT APPROACH TO OBESITY AND ITS COMPLICATIONS

As with any disease state, the management of it requires an understanding of how severe the disease is. For obesity, management guidelines have slowly moved from a BMI-centric approach, where the goal of therapy is to lose a given amount of weight (e.g., 5-10 percent), to a complications-centric approach, where weight is no longer the major determinant of appropriate treatment but now based on the risk, presence, and severity of obesity-related complications.²⁴ For example, at least 10 percent weight loss is needed to significantly improve NAFLD and OSA.²⁴ Hence, for a person with multiple complications, which include NAFLD and OSA, modest weight loss (defined as 5-10 percent weight loss) may be inadequate, and more aggressive treatment options, effecting more than modest weight loss, need to be considered. Although more aggressive treatment may involve higher risks, the benefits of treating the various obesity-related complications should outweigh these risks. Therefore, the main goal of therapy now is to treat or prevent obesity-related complications, rather than lose weight per se.

In line with this paradigm shift, the Working Group on Obesity, Diabetes, and the High-risk Patient from the European Society for Hypertension, and the European Association for the Study of Obesity published a consensus document that discusses the mechanisms of obesity-induced hypertension, diabetes, and dyslipidaemia, and highlights practice guidelines for the treatment of these conditions.²⁵ Essentially, this document calls for treatment of the underlying obesity in people with obesity-induced hypertension, diabetes, and dyslipidaemia. Hence, for some of these people, the first medication may not be an anti-hypertensive medication (for example) but an anti-obesity medication.

The other important point is that medications to treat these conditions should not worsen the underlying obesity, hence awareness of the potential weight effects when selecting pharmacologic agents for the treatment for these conditions is important. For example, sulphonylureas promote weight gain and should be avoided in patients with obesity as far as possible.

IMPORTANCE OF A MULTI-LEVEL AND INDIVIDUALISED MULTI-PRONGED APPROACH TO TREATING OBESITY

It is now known that the simple calculations underlying the traditional adage of “eat less, exercise more” are fatally flawed.²⁶ Aiming for a 500 kcal deficit (energy expenditure more than energy intake) per day, cumulating to 3,500 kcal per week (equivalent to -0.5 kg of fat) will not result in a 0.5 kg/week weight loss indefinitely, because this calculation does not consider the homeostatic mechanisms that will resist further weight loss, and in fact, will conspire to regain weight to restore the original “set point”.^{7,8,26} Additionally,

it is important to note that the same diet and exercise plan (often prescribed once in the beginning) will not suffice to maintain that 500 kcal deficit per day as a declining weight will mean declining energy expenditure.²⁶

Nonetheless, the point here is that asking all people with obesity to just “eat less and exercise more” overly simplifies the obesity problem. An understanding of the biology of weight regulation and the appreciation of the complex and multifactorial nature of how this regulation can go wrong resulting in obesity would indicate that there is no one-size-fits-all intervention or solution²⁷ and would necessitate a multi-level and individualised multi-pronged approach to treating obesity. Multi-level, apart from the individual, would include the social and community, physical (environment), and economic levels of interventions,²⁷ while a multi-pronged approach at the individual level would encompass not just the lifestyle and behavioural modifications but also the possible combination with pharmacologic and even bariatric surgical procedures based on individualised risk-benefit assessment.^{10,24}

DIETARY APPROACHES TO OBESITY TREATMENT

Lifestyle management remains a cornerstone in a multi-pronged approach to the treatment of obesity, and dietary modification is foundational in this management. General dietary advices that have Randomised Controlled Trials (RCT) level of evidence include decreasing sugar-sweetened beverages and portion control (e.g., plate concept),²⁸ both of which can be routinely advocated. More specific dietary approaches can be broadly categorised into energy-focused (e.g., use of meal replacements, low/very low energy diets), macronutrient-focused (e.g., low carbohydrate diet, low fat diet), dietary pattern-focused (e.g., DASH diet, Mediterranean diet), and dietary timing-focused (e.g., intermittent fasting, time-restricted feeding).²⁸ These diets usually involve some form of controlled intake and will on average induce weight loss if followed strictly.^{10,28} Hence, adherence to diet seems to be key as long-term diet trials have not shown a clear superiority of one diet over another with respect to average weight loss.^{10,26}

However, while patient preference plays a part in adherence, the preceding discussion on the biology of weight regulation informs us that homeostatic mechanisms such as increased hunger and cravings will be triggered upon weight loss, posing a challenge to diet adherence in the long term. Therefore, the satiating effect of a diet may become particularly important for long-term dietary adherence and weight maintenance. For example, diets with high amounts of protein (protein has a greater satiating effect compared with carbohydrates and fats), especially when the overall diet has a low glycaemic index, has been shown to be more beneficial for maintaining weight loss,²⁶ and there is the suggestion that meals containing carbohydrates may have a weaker satiating effect on individuals with impaired glucose metabolism. Hence, obese individuals with impaired glucose

metabolism may benefit more from a diet with higher fat and protein.^{29,30}

FINALLY: A BRIEF UPDATE ON INTERMITTENT FASTING

Recent years have seen a surge in popularity of timing-focused dietary approaches whereby such eating patterns involve restricting energy intake by varying degrees for a pre-defined period and eating *ad libitum* (i.e., to satisfy appetite) at all other times.³¹ These can range from complete (no energy containing foods or beverages consumed) alternate day fasting, to modified fasting regimens that allow the consumption of 20-25 percent of energy needs on scheduled fasting days (e.g., alternate days, two days per week [the “5:2 diet”]), to time-restricted feeding (which allows *ad libitum* energy intake within specific time frames inducing regular, extended fasting periods), and finally, to a variety of fasting regimens undertaken for religious or spiritual purposes.³²

Based on the current available evidence in humans, it appears that almost any intermittent fasting regimen can result in some weight loss and improvements in multiple health indicators including insulin resistance and reductions in risk factors for cardiovascular disease, through multiple pathways including reducing oxidative stress, optimisation of circadian rhythms, and ketogenesis, with no significant harm demonstrated.³²⁻³⁴ However, human studies have largely been limited to observational studies of religious fasting, cross-sectional studies of eating patterns associated with health outcomes, and experimental studies with modest sample sizes.³² Hence, large-scale randomised trials of longer duration (>1 year) are needed for more conclusive evidence on efficacy and potential harm so that sound recommendations can be made.³²

In any case, consistent with points made in the preceding sections, intermittent fasting could potentially be a treatment option but unlikely to be that “silver bullet”, and the treatment of obesity would still require a multi-level and individualised multi-pronged approach.

CONCLUSION

Obesity is now recognised as a disease and has been described as a complex, chronic medical condition with a major negative impact on human health. Several associations and organisations, including the World Health Organisation (WHO), have now declared obesity as a disease, and this is an important first step to tackling the problem of obesity. An understanding of the biology of weight regulation and the appreciation of the complex and multifactorial nature of how this regulation can go wrong resulting in obesity would indicate that there is no one-size-fits-all intervention or solution and would necessitate a multi-level and individualised multi-pronged approach to treating obesity and its related conditions.

REFERENCES

1. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet*. 2016 Apr 2;387(10026):1377-1396. doi: 10.1016/S0140-6736(16)30054-X. Erratum in: *Lancet*. 2016 May 14;387(10032):1998. PMID: 27115820.
2. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. *Metabolism*. 2019 Mar;92:6-10. doi: 10.1016/j.metabol.2018.09.005. Epub 2018 Sep 22. PMID: 30253139.
3. Ministry of Health, Singapore, National Health Survey 2010, EDC Division, Editor. 2011, Ministry of Health, Singapore: Singapore.
4. Epidemiology & Disease Control Division and Policy, RSG, Ministry of Health and Health Promotion Board, Singapore, National Population Health Survey 2022. 2023: Singapore.
5. Yu YH, Vasselli JR, Zhang Y, Mechanick JI, Korner J, Peterli R. Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications. *Obes Rev*. 2015 Mar;16(3):234-47. doi: 10.1111/obr.12246. Epub 2015 Jan 14. PMID: 25588316; PMCID: PMC5053237.
6. Morton GJ, Blevins JE, Williams DL, et al. Leptin action in the forebrain regulates the hindbrain response to satiety signals. *J Clin Invest*. 2005 Mar;115(3):703-10. doi: 10.1172/JCI22081. PMID: 15711637; PMCID: PMC548313.
7. Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. *Clin Sci (Lond)*. 2013 Feb;124(4):231-41. doi: 10.1042/CS20120223. PMID: 23126426.
8. Maclean PS, Bergouignan A, Cornier MA, Jackman MR. Biology's response to dieting: the impetus for weight regain. *Am J Physiol Regul Integr Comp Physiol*. 2011 Sep;301(3):R581-600. doi: 10.1152/ajpregu.00755.2010. Epub 2011 Jun 15. PMID: 21677272; PMCID: PMC3174765.
9. Farr OM, Li CR, Mantzoros CS. Central nervous system regulation of eating: Insights from human brain imaging. *Metabolism*. 2016 May;65(5):699-713. doi: 10.1016/j.metabol.2016.02.002. Epub 2016 Feb 6. PMID: 27085777; PMCID: PMC4834455.
10. González-Muniesa P, Martínez-González MA, Hu FB, et al. Obesity. *Nat Rev Dis Primers*. 2017 Jun 15;3:17034. doi: 10.1038/nrdp.2017.34. PMID: 28617414.
11. Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a Disease. *Med Clin North Am*. 2018 Jan;102(1):13-33. doi: 10.1016/j.mcna.2017.08.004. Epub 2017 Oct 21. PMID: 29156181.
12. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. *N Engl J Med*. 2017 Jan 19;376(3):254-266. doi: 10.1056/NEJMr1514009. PMID: 28099824.
13. Tam V, Turcotte M, Meyre D. Established and emerging strategies to crack the genetic code of obesity. *Obes Rev*. 2019 Feb;20(2):212-240. doi: 10.1111/obr.12770. Epub 2018 Oct 23. PMID: 30353704.
14. Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Hum Mol Genet*. 2018 Oct 15;27(20):3641-3649. doi: 10.1093/hmg/ddy271. PMID: 30124842; PMCID: PMC6488973.
15. Singh RK, Kumar P, Mahalingam K. Molecular genetics of human obesity: A comprehensive review. *C R Biol*. 2017 Feb;340(2):87-108. doi: 10.1016/j.crv.2016.11.007. Epub 2017 Jan 13. PMID: 28089486.
16. Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. *Genome Med*. 2016 Apr 20;8(1):42. doi: 10.1186/s13073-016-0303-2. PMID: 27098727; PMCID: PMC4839080.
17. Rial SA, Karelis AD, Bergeron KF, Mounier C. Gut Microbiota and Metabolic Health: The Potential Beneficial Effects of a Medium Chain Triglyceride Diet in Obese Individuals. *Nutrients*. 2016 May 12;8(5):281. doi: 10.3390/nu8050281. PMID: 27187452; PMCID: PMC4882694.
18. Stephens RW, Arhire L, Covasa M. Gut Microbiota: From Microorganisms to Metabolic Organ Influencing Obesity. *Obesity (Silver Spring)*. 2018 May;26(5):801-809. doi: 10.1002/oby.22179. PMID: 29687647.

19. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science*. 2013 Sep 6;341(6150):1241214. doi: 10.1126/science.1241214. PMID: 24009397; PMCID: PMC3829625.
20. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes*. 2007 Jul;56(7):1761-72. doi: 10.2337/db06-1491. Epub 2007 Apr 24. PMID: 17456850.
21. Cuthbertson DJ, Steele T, Wilding JP, et al. What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications? *Int J Obes (Lond)*. 2017 Jun;41(6):853-865. doi: 10.1038/ijo.2017.4. Epub 2017 Jan 12. PMID: 28077863.
22. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser*. 2000;894:i-xii, 1-253. PMID: 11234459.
23. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014 Aug 30;384(9945):766-81. doi: 10.1016/S0140-6736(14)60460-8. Epub 2014 May 29. Erratum in: *Lancet*. 2014 Aug 30;384(9945):746. PMID: 24880830; PMCID: PMC4624264.
24. Cefalu WT, Bray GA, Home PD, et al. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. *Diabetes Care*. 2015 Aug;38(8):1567-82. doi: 10.2337/dc15-1081. PMID: 26421334; PMCID: PMC4831905.
25. Kotsis V, Jordan J, Micic D, et al. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. *J Hypertens*. 2018 Jul;36(7):1427-1440. doi: 10.1097/HJH.0000000000001730. PMID: 29634663.
26. Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of Obesity. *Med Clin North Am*. 2018 Jan;102(1):183-197. doi: 10.1016/j.mcna.2017.08.012. PMID: 29156185; PMCID: PMC5764193.
27. Amarasinghe A, D'Souza G. Individual, Social, Economic, and Environmental Model: A Paradigm Shift for Obesity Prevention. *International Scholarly Research Notices*. 2012 Nov;2012:1-10. <https://doi.org/10.5402/2012/571803>.
28. Raynor HA, Champagne CM. Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults. *J Acad Nutr Diet*. 2016 Jan;16(1):129-147. doi: 10.1016/j.jand.2015.10.031. PMID: 26718656.
29. Hjorth MF, Ritz C, Blaak EE, et al. Pretreatment fasting plasma glucose and insulin modify dietary weight loss success: results from 3 randomized clinical trials. *Am J Clin Nutr*. 2017 Aug;106(2):499-505. doi: 10.3945/ajcn.117.155200. Epub 2017 Jul 5. PMID: 28679551.
30. Hwang JJ, Jiang L, Hamza M, et al. Blunted rise in brain glucose levels during hyperglycemia in adults with obesity and T2DM. *JCI Insight*. 2017 Oct 19;2(20):e95913. doi: 10.1172/jci.insight.95913. PMID: 29046482; PMCID: PMC5846903.
31. Seimon RV, Roekenes JA, Zibellini J, et al. Do intermittent diets provide physiological benefits over continuous diets for weight loss? A systematic review of clinical trials. *Mol Cell Endocrinol*. 2015 Dec 15;418 Pt 2:153-72. doi: 10.1016/j.mce.2015.09.014. Epub 2015 Sep 16. PMID: 26384657.
32. Patterson RE, Sears DD. Metabolic Effects of Intermittent Fasting. *Annu Rev Nutr*. 2017 Aug 21;37:371-393. doi: 10.1146/annurev-nutr-071816-064634. Epub 2017 Jul 17. PMID: 28715993.
33. Mattson MP, Longo VD, Harvie M. Impact of intermittent fasting on health and disease processes. *Ageing Res Rev*. 2017 Oct;39:46-58. doi: 10.1016/j.arr.2016.10.005. Epub 2016 Oct 31. PMID: 27810402; PMCID: PMC5411330.
34. Dong TA, Sandesara PB, Dhindsa DS, et al. Intermittent Fasting: A Heart Healthy Dietary Pattern? *Am J Med*. 2020 Aug;133(8):901-907. doi: 10.1016/j.amjmed.2020.03.030. Epub 2020 Apr 21. PMID: 32330491; PMCID: PMC7415631.

LEARNING POINTS

- **Obesity is now recognised as a chronic disease that needs chronic treatment to treat or prevent obesity-related complications.**
 - **The complex and multifactorial nature of obesity means that there is no one-size-fits-all intervention or solution and would necessitate a multi-level and individualised multi-pronged approach to treating obesity and its related conditions.**
 - **Dietary approaches such as intermittent fasting could potentially be a treatment option but it is unlikely to be that “silver bullet”.**
-